nodes	percent_of_prediction	percent_of_DWPC	metapath
Bevantolol—Tamsulosin—DRD3—Gilles de la Tourette syndrome	0.0476	0.591	CrCbGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0364	0.0396	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0356	0.0387	CbGpPWpGaD
Bevantolol—Tamsulosin—DRD2—Gilles de la Tourette syndrome	0.0329	0.409	CrCbGaD
Bevantolol—ADRB1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0311	0.0338	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0304	0.033	CbGpPWpGaD
Bevantolol—ADRB1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0301	0.0328	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0295	0.0321	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0295	0.032	CbGpPWpGaD
Bevantolol—ADRB1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0281	0.0305	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0275	0.0299	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0261	0.0284	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0255	0.0278	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0253	0.0276	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0251	0.0273	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0248	0.027	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0244	0.0265	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0236	0.0257	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0231	0.0251	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0227	0.0247	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0211	0.023	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0205	0.0223	CbGpPWpGaD
Bevantolol—ADRB1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0197	0.0214	CbGpPWpGaD
Bevantolol—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0192	0.0209	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0191	0.0208	CbGpPWpGaD
Bevantolol—ADRB1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0165	0.018	CbGpPWpGaD
Bevantolol—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.0164	0.0178	CbGpPWpGaD
Bevantolol—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0162	0.0176	CbGpPWpGaD
Bevantolol—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0159	0.0173	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.0135	0.0147	CbGpPWpGaD
Bevantolol—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0134	0.0145	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.0131	0.0142	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.00855	0.0093	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00599	0.00652	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00586	0.00638	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00582	0.00633	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00569	0.00619	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00542	0.00589	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0053	0.00577	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00513	0.00558	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00502	0.00546	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00498	0.00542	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00488	0.0053	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00485	0.00527	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00471	0.00512	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00464	0.00505	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00454	0.00494	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00439	0.00477	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00415	0.00452	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00403	0.00439	CbGpPWpGaD
Bevantolol—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.00397	0.00432	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00391	0.00425	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00382	0.00416	CbGpPWpGaD
Bevantolol—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.0038	0.00413	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.0038	0.00413	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00376	0.00409	CbGpPWpGaD
Bevantolol—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00371	0.00404	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00371	0.00404	CbGpPWpGaD
Bevantolol—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.00355	0.00386	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00354	0.00385	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00346	0.00376	CbGpPWpGaD
Bevantolol—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00325	0.00354	CbGpPWpGaD
Bevantolol—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00318	0.00346	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00316	0.00344	CbGpPWpGaD
Bevantolol—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00307	0.00334	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00307	0.00334	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00286	0.00311	CbGpPWpGaD
Bevantolol—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00263	0.00286	CbGpPWpGaD
Bevantolol—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00248	0.00269	CbGpPWpGaD
Bevantolol—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00242	0.00263	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00221	0.0024	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00216	0.00235	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00214	0.00233	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.0021	0.00228	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00201	0.00218	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.002	0.00218	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.002	0.00217	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00196	0.00213	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00195	0.00213	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00195	0.00212	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00191	0.00207	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00181	0.00197	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00179	0.00194	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00178	0.00193	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00174	0.00189	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00162	0.00177	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.00162	0.00176	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00158	0.00171	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00147	0.0016	CbGpPWpGaD
Bevantolol—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.0014	0.00152	CbGpPWpGaD
Bevantolol—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00137	0.00149	CbGpPWpGaD
Bevantolol—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00127	0.00138	CbGpPWpGaD
Bevantolol—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00124	0.00135	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00119	0.00129	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00116	0.00126	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00115	0.00125	CbGpPWpGaD
Bevantolol—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00113	0.00123	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00113	0.00122	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00107	0.00117	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.00105	0.00114	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00103	0.00112	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000959	0.00104	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000931	0.00101	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000867	0.000943	CbGpPWpGaD
Bevantolol—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000751	0.000817	CbGpPWpGaD
Bevantolol—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000734	0.000799	CbGpPWpGaD
Bevantolol—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000607	0.000661	CbGpPWpGaD
